Ertiprotafib
This product is for research use only, not for human use. We do not sell to patients.
For small sizes, please check our retail website as below: www.invivochem.com
| Size | Price | Stock |
|---|---|---|
| 100mg | $1650 | To Be Confirmed |
| 200mg | $2475 | To Be Confirmed |
| 500mg | $4175 | To Be Confirmed |
: Cat #: V20694 CAS #: 251303-04-5 Purity ≥ 99%
Description: Ertiprotafib (PTP-112; PTP112) is a novel and potent Protein Tyrosine Phosphatase 1B Inhibitor (PTP1B inhibitor) with the ability to normalize the plasma glucose and insulin levels in diabetic animal models.
Top Publications Citing Invivochem Products
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
| Molecular Weight (MW) | 559.51 |
|---|---|
| Molecular Formula | C31H27BrO3S |
| CAS No. | 251303-04-5 |
| SMILES Code | O=C(O)[C@H](OC1=C(C)C=C(C2=C(C(C)=C(C)S3)C3=C(Br)C4=CC=CC=C24)C=C1C)CC5=CC=CC=C5 |
| Synonyms | PTP-112; PTP112; PTP 112; Ertiprotafib |
| Protocol | In Vitro | Ertiprotafib is at least a dual PPARα and PPARβ agonist with EC50 values for transactivation of 1 μM. Such activities readily explain the observations with suprapharmacologic doses of these. |
|---|---|---|
| In Vivo | As seen with treatment of ob/ob mice, both Ertiprotafib and compound 3 seem to significantly improve glucose metabolism in rats. At 25 mg/kg/day, these compounds decrease both fasting blood glucose and insulin levels compared with vehicle treated rats. Furthermore, both Ertiprotafib and compound 3 increase glucose disposal after an oral challenge. It is noteworthy that lipid levels are also reduced in treated animals. Both triglyceride and free fatty acid levels are substantially reduced in rats treated with 25 mg/kg/day of either compound. To summarize, both Ertiprotafib and compound 3 seem to be robust agents in improving glucose utilization in fa/fa rats while also decreasing lipid levels in these animals. Decreased lipid levels may be unexpected for a pure PTP1b inhibitor. It is more telling, as mentioned above, that rats treated with suprapharmacologic doses of Ertiprotafib show signs of PPAR family activation. |
These protocols are for reference only. InvivoChem does not
independently validate these methods.
| Solvent volume to be added | Mass (the weight of a compound) | |||
|---|---|---|---|---|
| Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
| 1mM | 1.7873 mL | 8.9364 mL | 17.8728 mL | 35.7456 mL |
| 5mM | 0.3575 mL | 1.7873 mL | 3.5746 mL | 7.1491 mL |
| 10mM | 0.1787 mL | 0.8936 mL | 1.7873 mL | 3.5746 mL |
| 20mM | 0.0894 mL | 0.4468 mL | 0.8936 mL | 1.7873 mL |
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
=
Concentration
×
Volume
×
Molecular Weight*
The dilution calculator equation
Concentration(start)
×
Volume(start)
=
Concentration(final)
×
Volume(final)
This equation is commonly abbreviated as: C1 V1 = C2 V2
Concentration(start)
C1
×
Volume(start)
V1
=
Concentration(final)
C2
×
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg
Average weight of animals g
Dosing volume per animal µL
Number of animals
Step Two: Enter the in vivo formulation
%DMSO
+
%
+
%Tween 80
+
%ddH2O
Calculation Results:
Working concentration:
mg/ml;
Method for preparing DMSO master liquid:
mg
drug pre-dissolved in
µL
DMSO(Master liquid concentration
mg/mL)
,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:
Take
µL
DMSO master liquid, next add
µL
PEG300, mix and clarify, next add
µL
Tween 80,mix and clarify, next add
µL
ddH2O,mix and clarify.
Note:
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.